Rapamycin vs Metformin: The Two Longevity Drugs Compared

Rapamycin and metformin are the two drugs most often name-checked in longevity circles, and both are being used off-label by people who have never had the conditions they were approved to treat. That popularity has outrun the evidence. Here is what separates the two, and what neither one has actually proven.

What each drug was built for

Metformin is a first-line type 2 diabetes medication that has been prescribed for decades. It lowers blood glucose primarily by reducing liver glucose production and improving insulin sensitivity, and its safety profile in diabetics is well established.

Rapamycin (sirolimus) is an immunosuppressant, originally developed to prevent organ transplant rejection and later used in drug-eluting cardiac stents and as a cancer therapy in some contexts. It works by inhibiting mTOR (mechanistic target of rapamycin), a central regulator of cell growth, protein synthesis, and autophagy. Longevity interest in rapamycin comes directly from its mechanism: mTOR inhibition is one of the most consistently reproduced ways to extend lifespan in laboratory animals.

The animal evidence: not close

This is where the two drugs diverge sharply.

Rapamycin has been tested repeatedly by the National Institute on Aging’s Interventions Testing Program (ITP), a multi-site program specifically designed to replicate aging interventions across genetically diverse mouse cohorts. Rapamycin extended median and maximum lifespan in these mice at multiple doses and even when started relatively late in life — a result few other compounds have matched. It is widely regarded among aging researchers as having the most robust and reproducible lifespan-extension data of any pharmacological intervention tested to date.

Metformin’s animal data is far more mixed. Some mouse studies have shown modest lifespan extension, but results have been inconsistent across strains and doses, and metformin has not shown the same late-life, cross-cohort reproducibility that rapamycin has in the ITP. Metformin’s longevity reputation in humans comes largely from observational studies — for example, retrospective comparisons suggesting that diabetics on metformin sometimes had better survival outcomes than non-diabetic controls. Those comparisons are confounded in ways that are hard to fully correct for: people prescribed metformin differ systematically from people who are not, in ways beyond the drug itself.

Neither rapamycin nor metformin has a completed randomized controlled trial showing it extends human lifespan — the entire “longevity drug” case for both currently rests on animal data, mechanism, and observational associations in humans.

Human trials: proposed versus absent

Metformin has an actual human trial designed around the longevity question: TAME (Targeting Aging with Metformin), proposed by researchers including Nir Barzilai. TAME was designed as a large, multi-year trial studying whether metformin delays the onset of age-related conditions like heart disease, cancer, and cognitive decline in older adults without diabetes. It has been discussed for years as a landmark study, but it has faced significant funding and logistical hurdles and has not produced the definitive readout it was designed to generate. Smaller trials and secondary analyses of metformin in non-diabetics exist, but none settle the core longevity question.

Rapamycin has no equivalent human trial in progress at meaningful scale. Human data is limited to safety and pharmacokinetic studies, small trials in specific populations (including some work on immune function in older adults, and studies in companion dogs), and case reports from off-label users. There is genuine scientific interest in running human rapamycin trials, but nothing resembling the animal-model evidence currently exists in people.

Risks that get underweighted

Rapamycin’s clinical use as a transplant immunosuppressant means its risk profile at therapeutic doses is well documented: immune suppression, delayed wound healing, elevated cholesterol and triglycerides, mouth sores, and increased infection risk. Longevity users typically take much lower, intermittent doses than transplant patients, and some researchers argue this reduces risk substantially — but that dosing strategy has not been validated in long-term human safety studies, and immune effects at “longevity doses” are not well characterized.

Metformin is generally well tolerated but is not risk-free. Gastrointestinal side effects are common. Rare but serious lactic acidosis risk exists, particularly with kidney impairment. More relevant to healthy, exercising adults: several studies have suggested metformin may blunt some training adaptations, including reductions in the aerobic fitness gains typically seen from endurance exercise. For someone taking metformin specifically to extend healthy lifespan, potentially undercutting the benefits of exercise — one of the best-supported longevity interventions there is — is a real tradeoff to weigh.

Rapamycin vs metformin at a glance

	Rapamycin (sirolimus)	Metformin
Original approval	Transplant rejection prevention	Type 2 diabetes
Mechanism	mTOR inhibition	Lowers hepatic glucose output, improves insulin sensitivity
Animal lifespan data	Strong, reproducible (NIA ITP)	Mixed, inconsistent across studies
Human longevity trial	None at scale	TAME proposed, not completed/fully funded
Key risk	Immune suppression, lipid changes	GI upset, possible blunted exercise adaptations
Off-label longevity use	Growing, low-dose/intermittent protocols	Common, often alongside metformin’s diabetes use

The takeaway

Rapamycin has the more compelling laboratory case; metformin has the more plausible human safety record and an actual (if stalled) human trial designed to test the longevity question directly. Neither has proof in people. Anyone considering either drug off-label is making a bet on animal data and mechanism, not a demonstrated human outcome, and should discuss the real risks — immune effects for rapamycin, interactions with exercise and kidney function for metformin — with a clinician who can weigh them against personal health history.

Sources

• Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786175/
• National Institute on Aging. Interventions Testing Program. https://www.nia.nih.gov/research/dab/interventions-testing-program-itp
• Konopka AR, et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell. 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612634/
• American Federation for Aging Research. TAME Trial (Targeting Aging with Metformin). https://www.afar.org/tame-trial